Skip to content
Benefits & EvidenceEvidence-Tiered

ARA-290 Benefits

What does ARA-290 actually do? We break down the evidence by tier — human data, animal studies, and in vitro research — with citations for every claim.

Quick Answer

ARA-290's primary researched benefits include improved small nerve fiber density, reduction of neuropathic pain, and tissue protection without erythropoietic stimulation. Clinical trials have demonstrated efficacy in sarcoidosis and diabetic neuropathy. Mechanism involves activation of the innate repair receptor and anti-inflammatory signaling. Further research is ongoing for other tissue-protective applications.

→ ARA-290 Dosage→ ARA-290 Side Effects→ Full ARA-290 Profile

Evidence Tiers

HumanClinical or observational human dataAnimalPreclinical in vivo studiesIn VitroCell / tissue culture studies
Table of Contents

Mechanism of Action

ARA-290 selectively binds to the innate repair receptor (IRR), a heterodimer of EPOR and CD131, activating downstream signaling pathways like JAK2/STAT5 and PI3K/Akt. This leads to anti-apoptotic effects, suppression of NF-κB-mediated inflammation, promotion of Schwann cell survival, and axonal regeneration. ARA-290 does not activate the classical EPOR homodimer, avoiding erythropoiesis and related cardiovascular risks.

Human Evidence

Human2 findings

Improved Small Nerve Fiber Density

Clinical trials demonstrated significant increases in corneal and skin nerve fiber density in sarcoidosis patients treated with ARA-290 for 28 days.

PubMed 25420513 (2014) ↗

Reduced Neuropathic Pain

Patients with sarcoidosis and diabetic neuropathy reported significant reductions in neuropathic pain scores following ARA-290 treatment.

PubMed 22357357 (2012) ↗

Animal Studies

Animal2 findings

Tissue Protection in Ischemic Models

Animal studies have shown ARA-290 to provide tissue protection in models of ischemia, including cardioprotective effects via anti-apoptotic signaling.

PubMed 20861672 (2010) ↗

Anti-inflammatory Effects

In animal models, ARA-290 has demonstrated anti-inflammatory effects through suppression of NF-κB signaling.

PubMed 20861672 (2010) ↗

In Vitro Research

In Vitro1 finding
In vitro (cell culture) findings are the earliest stage of evidence. They indicate mechanism plausibility but cannot confirm human effects.

Activation of IRR Signaling Pathways

In vitro studies have confirmed that ARA-290 selectively activates the innate repair receptor (IRR) and downstream signaling pathways like JAK2/STAT5 and PI3K/Akt.

PubMed 20861672 (2010) ↗

What's Proven vs What's Still Unknown

✓ What the Evidence Supports

  • ✓Improves small nerve fiber density in sarcoidosis patients
  • ✓Reduces neuropathic pain in clinical trials
  • ✓Activates the innate repair receptor (IRR)
  • ✓Demonstrates tissue-protective effects in animal models
  • ✓Exhibits anti-inflammatory properties

? Still Unknown or Unconfirmed

  • ?Long-term efficacy and safety profile
  • ?Optimal dosing for various conditions
  • ?Efficacy for other neuropathic conditions beyond sarcoidosis and diabetes
  • ?Cardioprotective effects in humans

Frequently Asked Questions

What are the most evidence-backed benefits of ARA-290?
The strongest evidence supports its ability to improve small nerve fiber density and reduce neuropathic pain in patients with sarcoidosis-associated neuropathy, based on phase 2 clinical trial data.
Has ARA-290 been tested in humans?
Yes, ARA-290 has completed phase 2 clinical trials in humans for sarcoidosis-associated neuropathy and diabetic neuropathy. These trials have shown promising results in improving nerve fiber density and reducing pain.
How does ARA-290 promote healing and tissue protection?
ARA-290 selectively activates the innate repair receptor (IRR), triggering anti-apoptotic pathways, suppressing inflammation, promoting Schwann cell survival, and facilitating nerve fiber repair, ultimately leading to tissue protection and regeneration.
Can ARA-290 help with other conditions involving nerve damage?
While clinical trials have primarily focused on sarcoidosis and diabetic neuropathy, ARA-290 may have potential benefits for other conditions involving small nerve fiber damage, chronic pain, and tissue injury. Further research is needed to explore these applications.
Is ARA-290 an anti-inflammatory?
Yes, ARA-290 exhibits anti-inflammatory properties by suppressing NF-κB-mediated inflammation, which contributes to its tissue-protective effects.
What is the difference between ARA-290 and Erythropoietin (EPO)?
ARA-290 is derived from EPO but selectively activates the innate repair receptor (IRR) without stimulating red blood cell production (erythropoiesis). EPO activates the classical EPOR homodimer to stimulate red blood cell production, which carries risks of blood thickening and thrombosis. ARA-290 avoids these cardiovascular risks.

References

  1. 1
    ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes(2012)PubMed ↗
  2. 2
    Cibinetide (ARA 290) improves small nerve fiber density and pain in sarcoidosis patients: a randomized controlled trial(2014)PubMed ↗
  3. 3
    The innate repair receptor: a novel concept for tissue protection and repair mediated by the EPO receptor/CD131 heterodimer(2010)PubMed ↗
  4. 4
    Erythropoietin and Tissue Protection(2007)PubMed ↗
  5. 5
    Innate Immunity and Tissue Repair(2012)PubMed ↗

Last updated: 2026-02-19